On Tuesday, Nvidia stock rose 5% to a record closing price following announcements of new products, collaborations, and ...

NEW YORK (AP) — The U.S. stock market is pulling back from its record heights on Thursday, as Wall Street sifts through mixed ...

President Donald Trump is adjusting his messaging strategy to win over voters who are worried about the cost of living with ...

Beauty Goodies is a small business that specializes in chic storage and travel accessories.

Kerry Katona sees herself as a "great example" of turning your life around. The 45-year-old star thinks she would have ...

Barring an outright catastrophe during 2025's final innings, it's likely the full year will come and go without experiencing ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Oct 15 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Eli Lilly (NYSE:LLY) on Friday reported plans to acquire Adverum Biotechnologies (NASDAQ:ADVM) and its lead gene therapy candidate, Ixo-vec, sending Adverum shares soaring in premarket trading. Under ...

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...